Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan Q3 Roundup: Majors Enjoy Forex Windfall But COVID Returns Decline

Mainstays Mostly Strong

Executive Summary

While the weaker yen boosted the top line for Japanese pharma companies with a strong global presence in the fiscal first half, it also raised reported costs. Several firms reported strong growth for mainstays, while holding out high hopes for selected new drugs with blockbuster potential. But some other products underperformed for unexpected reasons.

You may also be interested in...

Japan Ends Full Coverage For COVID Therapeutics, Pharma Braces For Price Cuts

Japan has started the stepped reduction of reimbursement of COVID-19 drugs under its national health insurance scheme, aiming to lower this to standard levels by April 2024. Oral antiviral Xocova also looks set to receive a one-off special price cut, over which the local industry has expressed its concerns.

It’s Official: The Merck-Daiichi Deal Has The Biggest Upfront Ever

But the partners will have to avoid the pitfalls that have bedevilled several other expensive licensing deals.

Daiichi In Massive $22bn Global Deal With Merck & Co For Three ADCs

The two firms will co-develop and co-commercialize three Daiichi ADCs globally outside Japan in a deal the Japanese firm said would allow “more aggressive development plans targeting broader patient populations.” 

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts